<p>*Except when otherwise indicated, values are expressed as counted data (%). SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC: Systemic Lupus International Collaborating Clinics.</p><p>Demographic characteristics and clinical data according to SLICC criteria in the PLE and control groups<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114684#nt101" target="_blank">*</a></sup>.</p
*<p>Values are shown by mean ± SEM (range) or number (percentage). There were no significant differe...
<p>For the 29 patients with 2 visits, the age used is from their baseline visit indicated above.</p
To access publisher's full text version of this article. Please click on the hyperlink in Additional...
<p>* except where indicated otherwise, values are the number (%) of patients. SLE = Systemic Lupus E...
<p>SD: Standard Deviation; NP: NeuroPsychiatric; SLEDAI: Systemic Lupus Erythematosus Disease Activi...
<p>Values are median (interquartile range, IQR) unless stated otherwise; s.d., standard deviation; n...
<p>SD: Standard Deviation; NP: NeuroPsychiatric; SLEDAI: Systemic Lupus Erythematosus Disease Activi...
<p>Note: SLEDAI: Systemic Lupus Erythematosus Disease Activity Index</p><p>Clinical and pathological...
<p>Results are presented as means (SD) or number of affected individuals and (%).</p><p>SLE – system...
<p>CAD, coronary artery disease; BMI, body mass index; SELENA, safety of estrogens in lupus erythema...
<p>SD = standard deviation</p><p>IQR = interquartile range</p><p>ACR = American College of Rheumatol...
<p>* Manifestations are defined according to American College of Rheumatology’s 1982 revised criteri...
The objectives of this study were to analyse the performance of the Systemic Lupus International Col...
The objective was to determine the prevalence of the metabolic syndrome (MS) in patients with system...
Objective. Having developed and validated a disease-specific health-related quality of life (HRQOL) ...
*<p>Values are shown by mean ± SEM (range) or number (percentage). There were no significant differe...
<p>For the 29 patients with 2 visits, the age used is from their baseline visit indicated above.</p
To access publisher's full text version of this article. Please click on the hyperlink in Additional...
<p>* except where indicated otherwise, values are the number (%) of patients. SLE = Systemic Lupus E...
<p>SD: Standard Deviation; NP: NeuroPsychiatric; SLEDAI: Systemic Lupus Erythematosus Disease Activi...
<p>Values are median (interquartile range, IQR) unless stated otherwise; s.d., standard deviation; n...
<p>SD: Standard Deviation; NP: NeuroPsychiatric; SLEDAI: Systemic Lupus Erythematosus Disease Activi...
<p>Note: SLEDAI: Systemic Lupus Erythematosus Disease Activity Index</p><p>Clinical and pathological...
<p>Results are presented as means (SD) or number of affected individuals and (%).</p><p>SLE – system...
<p>CAD, coronary artery disease; BMI, body mass index; SELENA, safety of estrogens in lupus erythema...
<p>SD = standard deviation</p><p>IQR = interquartile range</p><p>ACR = American College of Rheumatol...
<p>* Manifestations are defined according to American College of Rheumatology’s 1982 revised criteri...
The objectives of this study were to analyse the performance of the Systemic Lupus International Col...
The objective was to determine the prevalence of the metabolic syndrome (MS) in patients with system...
Objective. Having developed and validated a disease-specific health-related quality of life (HRQOL) ...
*<p>Values are shown by mean ± SEM (range) or number (percentage). There were no significant differe...
<p>For the 29 patients with 2 visits, the age used is from their baseline visit indicated above.</p
To access publisher's full text version of this article. Please click on the hyperlink in Additional...